• Home
  • > Media & Investors
  • > Media Relations
  • > Press Releases
  • > Daiichi Sankyo and Kaketsuken to end sales cooperation for Influenza HA Vaccine “Kaketsuken” and hepatitis B vaccine Bimmugen®

For Immediate Release

2018.05.08

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and COO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Koji Ogawa, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com

Daiichi Sankyo and Kaketsuken to end sales cooperation for Influenza HA Vaccine “Kaketsuken” and hepatitis B vaccine Bimmugen®

Tokyo and Kumamoto, Japan (May 8, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and the Chemo-Sero-Therapeutic Research Institute (hereinafter, Kaketsuken) have announced the termination of their cooperative sales agreement for the Influenza HA Vaccine “Kaketsuken” on March 31, 2018, as well as their decision to terminate the cooperative sales agreement for the recombinant adsorbed hepatitis B vaccine, Bimmugen®(hereinafter, “Bimmugen®”) as of March 31, 2019.

 

Influenza HA Vaccine “Kaketsuken,” and Bimmugen® are manufactured by Kaketsuken and distributed via the respective sales companies. Through the strategic collaborations to further improve public health in Japan and expand the availability of preventive medicine, Kaketsuken and Daiichi Sankyo entered into cooperative sales agreements for Bimmugen® in August 2014 and for Influenza HA Vaccine “Kaketsuken” in May 2015, respectively, and have strived to expand the utilization of both products since then. However, after a review of sales strategy and discussions between the two companies, Kaketsuken and Daiichi Sankyo reached an agreement to terminate both cooperative sales agreements.

 

Kaketsuken and Daiichi Sankyo will continue making efforts toward further improvement of public health in Japan, as well as contributing to the prevention and treatment of diseases in order to improve public health of Japanese people through the manufacture and supply of medicines, including vaccines.

 

Cooperative Sales Termination products (termination date):

・ Influenza HA Vaccine “Kaketsuken” (March 31, 2018)

・ Bimmugen® 0.25mL, 0.5mL (March 31, 2019)